Not Signed In - Replidyne Commences Clinical Trials For REP8839
Wed, 19 Jul 2006 06:00 AM EST
... Replidyne, Inc.(Nasdaq: RDYN) announced today the initiation of Phase I clinical testingof its topical anti-infective drug candidate REP8839, being developed fortreatment of skin and wound infections and the prevention of S. aureusinfections including methicillin resistant S. aureus, or MRSA, infectionsin hospital settings. [click link for full article] ...
Related Topics
- Clinical Trials
- Pharmacology
- Psychopharmacology
- Clinical Growth Charts
- Pediatric Aids
- Hypnotherapy
- Epidemiology
- Clinical Laboratory Improvement Amendments
- Depression
- Infectious Diseases
- Western/Clinical Treatment and Therapy
- Epidemiology & Prevention of Vaccine-Preventable Diseases
- Trastuzumab
- Tarceva
- Bevacizumab Injection
- Nutrition
- Devil's Claw
- Nutrition & Physical Acitvity Surveys & Monitoring Systems
- Health psychology
- Crohn's Disease
email this page
print this page
bookmark this page
feedback on this page
